Results 201 to 210 of about 70,999 (292)

Effect of Essential Phospholipids in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Randomised Phase 4 Clinical Trial

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) poses a significant health burden and impacts quality of life (QoL). This study evaluates the effects of essential phospholipids (EPL) on liver steatosis, QoL, and other liver and metabolic parameters in patients with MASLD and associated comorbidities ...
Norbert Stefan   +9 more
wiley   +1 more source

Renal Shear Wave Elastography for Differentiating Vasculitic and Non-Vasculitic Acute Kidney Injury. [PDF]

open access: yesJ Clin Med
Yıldırım F   +11 more
europepmc   +1 more source

Clinical Outcomes and Non‐Invasive Testing in Metabolic Dysfunction‐Associated Steatohepatitis With Cirrhosis: A Systematic Review

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background and Aims Metabolic dysfunction‐associated steatohepatitis (MASH) with cirrhosis lacks definitive treatments and poses an increasing healthcare burden globally. We undertook a systematic literature review (SLR) to better understand the disease burden in cirrhosis due to MASH.
Hannes Hagström   +8 more
wiley   +1 more source

Prognostication of Liver Disease Patients via the WFUMB ‘Rule‐of‐4’ Algorithm Using SSI‐2D‐SWE‐Based Liver Stiffness Measurement

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background The World Federation for Ultrasound in Medicine and Biology (WFUMB) guidance update 2024 proposed a ‘rule‐of‐4’ using ARFI liver stiffness measurement (LSM) to stratify the risk of decompensation events. This rule identifies advanced chronic liver disease (ACLD) at a threshold of ≥ 13 kPa and indicates a high probability of ...
Christian Sebesta   +16 more
wiley   +1 more source

Elastographie, transiente [PDF]

open access: yes, 2017
A. M. Gressner, O. A. Gressner
openaire   +1 more source

Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background Portal vein thrombosis (PVT) is a common sequela of cirrhosis. Despite regression of fibrosis/cirrhosis observed among some patients after disease‐specific treatment, few studies have considered the role of treatment and response on risk of PVT among patients with cirrhosis across different liver disease states.
Humberto C. Gonzalez   +10 more
wiley   +1 more source

Radiomics‐Based Assessment of Portal Hypertension Severity and Risk Stratification of Cirrhotic Patients Using Routine CT Scans

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background & Aims To develop and validate a CT‐based radiomics model to assess HVPG and predict a composite endpoint of liver‐related events (LRE: decompensation and liver‐related death) in patients with cirrhosis. Methods This retrospective study included 357 cirrhosis patients, who received invasive HVPG measurements, 120 liver‐healthy ...
Celine Sin   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy